Gylden’s 2025 Strategic Priorities for Advancing Innovative and Transformative Solutions for Infectious Diseases
Clinical trials planned to begin patient enrollment during 2025 to [...]
Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
Abingdon, United Kingdom, 17 October 2024 – Emergex Vaccines Holding Limited, [...]
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
- NIAID will be conducting and sponsoring clinical trials to [...]
Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity
- Breakthrough patent represents a significant leap in influenza pandemic [...]
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products [...]
Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director
Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding [...]